The panel gives access to over 336,000 panelists in the US and Canada who have been diagnosed with either type 1 diabetes, type 2 diabetes, high blood pressure or obesity and aims to provide a resource for creating in-depth, multi-country insights on consumer ailment.

It is the first market research panel based around therapeutic areas to be launched by the company which will be rolling out a series of condition-based panels over the next twelve months.

Research Now senior vice-president of global healthcare Vincent DeRobertis said: “Our goal for this series is to be able to approach each condition uniquely, and focus on holistic solutions that will provide a deeper knowledge base of the condition.”